Pregnant women with systemic lupus erythematosus (SLE) carry higher risks for adverse maternal and fetus outcomes according to a recent study. The study, “What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE,” was published in the…
News
Scientists at the Hospital for Special Surgery (HSS) in New York, in collaboration with Greek researchers, may have identified a trigger for autoimmune disorders that could shed light on how many diseases develop, including lupus. The investigators found virus-like components of the human genome that seem to be…
Ann Marshak-Rothstein, professor of Medicine and Rheumatology at University of Massachusetts Memorial Medical School, received the 2016 Lupus Insight Prize for promising research to improve the treatment of the lupus-related skin disease called cutaneous lupus. The award was announced at the recent 16th Annual Meeting of the Federation of Clinical…
A bill recently moved forward by the U.S. Senate Appropriations Committee on labor, health human services and education for 2017 includes $6 million for lupus research and education, in addition to $34 billion for medical research overall at the National Institutes of Health (NIH). Specifically, the committee bill supports funding for the…
Regen BioPharma has identified small molecules that activate NR2F6, an immune checkpoint recently identified by the company. This is the first step in a series of initiatives to develop small molecules the biotech will use as the basis to create an oral drug with potent anti-inflammatory properties, or a checkpoint inhibitor pill.
Treatments for lupus systemic erythematosus (SLE) have greatly improved over time due to advances in the understanding of the condition. The past few decades, however, have not produced expected additional progress in lupus treatment. A new commentary from researchers in Spain reviews the current situation with lupus therapies, including their recommendations for…
Scientists at Bristol-Myers Squibb have uncovered mechanisms explaining why African-Americans with systemic lupus erythematosus (SLE) experience more serious symptoms and become sick at earlier ages than American patients of European descent. The difference lies in B-cells according to the study “B cells from African American lupus patients exhibit…
A bill recently passed by the U.S. Senate Appropriations Committee includes critical funding for lupus research and education. The Lupus Foundation of America (LFA) thanks the committee for supporting the funding bill, which has moved to the full Senate for consideration. If the bill is approved, it would bring an additional $6 million…
San Francisco-based Thunderbolt — the first company established by Vitesse Biologics — has attained the rights to Astellas Pharma’s BAFF/APRIL dual antagonist program — a therapeutic solution developed for systemic lupus erythematosus (SLE) as well as a range of B-cell disorders, according to a recent announcement from Baxalta,…
The Alliance for Children’s Therapeutics presented positive results from an early study of KPI Therapeutics/Kineta’s lead drug candidate, dalazatide, as a possible treatment for children and teenagers with lupus nephritis. The data were given at the recent European League Against Rheumatism’s 17th Annual Congress in London. A key finding was that “patients with…
Recent Posts
- Twin Phase 3 studies recruiting adults with lupus skin problems in US, Canada
- Understanding how menopause can affect our lupus symptoms
- Discovering a role the vagus nerve plays in chronic pain management
- Recognizing patterns is one of my greatest weapons against lupus flares
- Flaws on the X chromosome may directly trigger lupus in women